Trek Financial LLC Boosts Stake in Johnson & Johnson (NYSE:JNJ)

Trek Financial LLC raised its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 90.4% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,762 shares of the company's stock after acquiring an additional 1,786 shares during the quarter. Trek Financial LLC's holdings in Johnson & Johnson were worth $624,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in JNJ. DekaBank Deutsche Girozentrale raised its stake in Johnson & Johnson by 1.6% in the 1st quarter. DekaBank Deutsche Girozentrale now owns 4,483,071 shares of the company's stock valued at $731,462,000 after purchasing an additional 71,750 shares during the last quarter. OMNI 360 Wealth Inc. grew its holdings in shares of Johnson & Johnson by 57.2% during the first quarter. OMNI 360 Wealth Inc. now owns 5,221 shares of the company's stock worth $866,000 after buying an additional 1,899 shares in the last quarter. Personal CFO Solutions LLC raised its position in shares of Johnson & Johnson by 4.1% in the first quarter. Personal CFO Solutions LLC now owns 13,214 shares of the company's stock valued at $2,191,000 after buying an additional 526 shares during the last quarter. Opus Capital Group LLC lifted its stake in shares of Johnson & Johnson by 39.0% during the first quarter. Opus Capital Group LLC now owns 5,476 shares of the company's stock valued at $908,000 after buying an additional 1,537 shares during the period. Finally, CapWealth Advisors LLC boosted its position in Johnson & Johnson by 6.4% during the first quarter. CapWealth Advisors LLC now owns 146,078 shares of the company's stock worth $24,226,000 after acquiring an additional 8,829 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.

Johnson & Johnson Stock Down 0.5%

Shares of NYSE:JNJ traded down $0.82 during midday trading on Friday, hitting $156.87. 7,866,488 shares of the company's stock traded hands, compared to its average volume of 8,066,975. The firm's fifty day moving average price is $153.75 and its two-hundred day moving average price is $154.43. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.03 and a current ratio of 1.26. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99. The company has a market cap of $377.44 billion, a PE ratio of 17.45, a P/E/G ratio of 2.15 and a beta of 0.41.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, topping analysts' consensus estimates of $2.59 by $0.18. The company had revenue of $21.89 billion for the quarter, compared to analysts' expectations of $21.65 billion. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. On average, equities research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th were given a $1.30 dividend. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date was Tuesday, May 27th. This represents a $5.20 annualized dividend and a yield of 3.31%. Johnson & Johnson's dividend payout ratio (DPR) is 57.84%.

Analyst Ratings Changes

Several research analysts have weighed in on JNJ shares. Wall Street Zen upgraded Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a report on Saturday, June 21st. Raymond James Financial lowered their price objective on Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating for the company in a research report on Monday, April 14th. Benchmark upgraded Johnson & Johnson to a "strong-buy" rating in a research report on Thursday, April 24th. Leerink Partnrs cut Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a report on Tuesday, May 13th. Finally, Morgan Stanley reaffirmed an "underperform" rating on shares of Johnson & Johnson in a research note on Thursday. Eleven investment analysts have rated the stock with a hold rating, seven have given a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $171.00.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.